March 30, 2017 8:10 AM ET

Biotechnology

Company Overview of Ab Initio Biotherapeutics, Inc.

Company Overview

Ab Initio Biotherapeutics, Inc. develops protein therapeutics. The company engages in identification of activating and inactivating antibodies against G-protein coupled receptors. It also focuses on the development of drugs for cancer immunotherapy, including antibody agents and non-antibody biologics. The company has a strategic collaboration with Pfizer. Ab Initio Biotherapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

280 Utah Avenue

South San Francisco, CA 94080

United States

Founded in 2015

Key Executives for Ab Initio Biotherapeutics, Inc.

Co-Founder, Chief Executive Officer and President
Head of Biology
Head of Biochemistry
Compensation as of Fiscal Year 2016.

Ab Initio Biotherapeutics, Inc. Key Developments

Ab Initio Biotherapeutics, Inc. Announces Strategic Collaboration with Pfizer to Discover GPCR Activating Antibodies

Ab Initio Biotherapeutics, Inc. announced a collaborative research and license agreement with Pfizer Inc. that aims to discover novel therapeutic antibodies against an undisclosed target in the G-protein coupled receptor (GPCR) superfamily. GPCRs comprise the larger class of therapeutic drug targets, with key regulatory roles in physiological processes ranging from cardiovascular biology to metabolic health. Ab Initio will use its proprietary GPCR antibody discovery platform to help engineer antibodies that activate the targeted GPCR. Pfizer has exclusive worldwide rights to develop and commercialize any GPCR activator (agonist) antibodies against this target that may result from the collaboration. Ab Initio will receive an upfront fee and research support, and is eligible to receive milestone payments and tiered royalties on future sales of any products that may result from this collaboration. Further terms of the deal are not disclosed. In addition, Pfizer will make a strategic investment in Ab Initio alongside the Company’s existing investors.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
December 13, 2016
--
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Ab Initio Biotherapeutics, Inc., please visit www.aibio.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.